The use of mycophenolate mofetil suspension in pediatric renal allograft recipients
dc.contributor.author | Birk, P. | en_US |
dc.contributor.author | Greenbaum, L. | en_US |
dc.contributor.author | Lirenman, D. | en_US |
dc.contributor.author | Tang, H. | en_US |
dc.contributor.author | Walker, Rowan | en_US |
dc.contributor.author | Klamerus, K. | en_US |
dc.contributor.author | Navarro, Mercedes | en_US |
dc.contributor.author | Chavers, B. | en_US |
dc.contributor.author | Fong, A. | en_US |
dc.contributor.author | Sherbotie, Joseph R. | en_US |
dc.contributor.author | Thomas, S. | en_US |
dc.contributor.author | Tönshoff, B. | en_US |
dc.contributor.author | Zimmerhackl, L. B. | en_US |
dc.contributor.author | Clark, Godfrey. | en_US |
dc.contributor.author | Ettenger, Robert | en_US |
dc.contributor.author | Bunchman, Timothy E. | en_US |
dc.contributor.author | Arterburn, S. | en_US |
dc.contributor.author | Ramos, E. | en_US |
dc.contributor.author | Lerner, Gary | en_US |
dc.contributor.author | Blowey, D. | en_US |
dc.contributor.author | Broyer, M. | en_US |
dc.date.accessioned | 2006-09-08T20:11:45Z | |
dc.date.available | 2006-09-08T20:11:45Z | |
dc.date.issued | 2001-12 | en_US |
dc.identifier.citation | Bunchman, T.; Navarro, M.; Broyer, M.; Sherbotie, J.; Chavers, B.; Tönshoff, B.; Birk, P.; Lerner, G.; Lirenman, D.; Greenbaum, L.; Walker, R.; Zimmerhackl, L. B.; Blowey, D.; Clark, G.; Ettenger, R.; Arterburn, S.; Klamerus, K.; Fong, A.; Tang, H.; Thomas, S.; Ramos, E.; (2001). "The use of mycophenolate mofetil suspension in pediatric renal allograft recipients." Pediatric Nephrology 16(12): 978-984. <http://hdl.handle.net/2027.42/42304> | en_US |
dc.identifier.issn | 0931-041X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/42304 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11793083&dopt=citation | en_US |
dc.description.abstract | Mycophenolate mofetil (MMF) is widely used to prevent acute rejection in adults after renal, cardiac, and liver transplantation. This study investigated the safety, tolerability, and pharmacokinetics of MMF suspension in pediatric renal allograft recipients. One hundred renal allograft recipients were enrolled into three age groups (33 patients, 3 months to <6 years; 34 patients, 6 to <12 years; 33 patients, 12 to 18 years). Patients received MMF 600 mg/m 2 b.i.d. concomitantly with cyclosporine and corticosteroids with or without antilymphocyte antibody induction. One year after transplantation, patient and graft survival (including death) were 98% and 93%, respectively. Twenty-five patients (25%) experienced a biopsy-proven (Banff grade borderline or higher) or presumptive acute rejection within the first 6 months post-transplantation. Analysis of pharmacokinetic parameters for mycophenolic acid (MPA) and mycophenolic acid glucuronide showed no clinically significant differences among the age groups. The dosing regimen of MMF 600 mg/m 2 b.i.d. achieved the targeted early post-transplantation MPA 12-h area under concentration-time curve (AUC 0–12 ) of 27.2 µg h per ml. Adverse events had similar frequencies among the age groups (with the exception of diarrhea, leukopenia, sepsis, and anemia, which were more frequent in the <6 years age group) and led to withdrawal of MMF in about 10% of patients. Administration of MMF 600 mg/m 2 b.i.d. is effective in prevention of acute rejection, provides predictable pharmacokinetics, and is associated with an acceptable safety profile in pediatric renal transplant recipients. | en_US |
dc.format.extent | 88823 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag; IPNA - International Pediatric Nephrology Association New York, USA | en_US |
dc.subject.other | Legacy | en_US |
dc.subject.other | Keywords Mycophenolate Mofetil | en_US |
dc.subject.other | Mycophenolic Acid | en_US |
dc.subject.other | Pharmacokinetics | en_US |
dc.subject.other | Renal Transplantation | en_US |
dc.subject.other | Pediatric | en_US |
dc.title | The use of mycophenolate mofetil suspension in pediatric renal allograft recipients | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, Michigan, USA, US | en_US |
dc.contributor.affiliationother | UCLA Medical School, Los Angeles, California, USA, US | en_US |
dc.contributor.affiliationother | Medical College of Wisconsin, Milwaukee, Wisconsin, USA, US | en_US |
dc.contributor.affiliationother | Children’s Hospital, Los Angeles, California, USA, US | en_US |
dc.contributor.affiliationother | Royal Children’s Hospital, Melbourne, Australia, AU | en_US |
dc.contributor.affiliationother | Hôpital Necker-Enfants Malades, Paris, France, FR | en_US |
dc.contributor.affiliationother | Roche Pharmaceuticals, Palo Alto, California, USA, US | en_US |
dc.contributor.affiliationother | University of Alabama at Birmingham, 1600 7th Avenue South, Suite 735, Birmingham, Alabama 35233, USA. Tbunchman@peds.uab.edu, US | en_US |
dc.contributor.affiliationother | Children’s Mercy Hospital, Kansas City, Missouri, USA, US | en_US |
dc.contributor.affiliationother | Roche Pharmaceuticals, Palo Alto, California, USA, US | en_US |
dc.contributor.affiliationother | Roche Pharmaceuticals, Palo Alto, California, USA, US | en_US |
dc.contributor.affiliationother | Guy’s Hospital, London, UK, GB | en_US |
dc.contributor.affiliationother | Department of Pediatrics, University of Freiburg, Freiburg, Germany, DE | en_US |
dc.contributor.affiliationother | University of British Columbia, Vancouver, British Columbia, Canada, CA | en_US |
dc.contributor.affiliationother | University of Minnesota Medical School, Minneapolis, Minnesota, USA, US | en_US |
dc.contributor.affiliationother | University of Manitoba, Winnipeg, Manitoba, Canada, CA | en_US |
dc.contributor.affiliationother | University of Utah Health Sciences Center, Salt Lake City, Utah, USA, US | en_US |
dc.contributor.affiliationother | Roche Pharmaceuticals, Palo Alto, California, USA, US | en_US |
dc.contributor.affiliationother | Hospital Infantil La Paz, Madrid, Spain, ES | en_US |
dc.contributor.affiliationother | Roche Pharmaceuticals, Palo Alto, California, USA, US | en_US |
dc.contributor.affiliationother | University Children’s Hospital, Heidelberg, Germany, DE | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 11793083 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/42304/1/467-16-12-978_10160978.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s004670100006 | en_US |
dc.identifier.source | Pediatric Nephrology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.